1 / 23

MRD in ALL, technique and predictive value

MRD in ALL, technique and predictive value. 울산대학교 의과대학 서울아산병원 혈액내과 이 규 형. Utilization of disease markers. Goal. Survival prolongation Disease free survival prolongation Toxicity reduction Improved QOL Improved cost- effectiveness of care. Screening Differential Dx

geraldineg
Télécharger la présentation

MRD in ALL, technique and predictive value

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MRD in ALL, technique and predictive value 울산대학교 의과대학 서울아산병원 혈액내과 이 규 형

  2. Utilization of disease markers Goal • Survival prolongation • Disease free survival prolongation • Toxicity reduction • Improved QOL • Improved cost- effectiveness of care • Screening • Differential Dx • Prognostic factor • Disease follow-up

  3. (1) Level I : 가장 확실한 증거로 잘 수행된 meta-analysis 또는 많은 수의 환자를 대상으로한 동시대조군을 동반한 전향적 연구로 연구의 주 목적이 tumor marker 이용에 대한 평가이어야 한다. (2) Level II : 전향적 연구의 결과이나 연구의 주목적은 치료에 관한 가설을 검증하는 것이고 tumor marker의 평가는 부차적인 목적인 경우이다. 단 이 경우에도 tumor marker의 평가는 전향적으로 그 목적이 기술되어 있어야 한다. (3) Level III : 대규모 후향적 연구의 결과로 대개는 다변량 분석을 포함하는 연구이다. (4) Level IV : 후향적 연구의 결과로 환자의 숫자가 작거나 다변량 분석을 하지 않아 level III evidence의 연구보다 신뢰성이 떨어지는 경우이다. (5) Level V : 작은 규모의 후향적 연구로 연구의 design이 tumor marker 결과와 환자의 임상적 경과와의 상관관계를 알아보는 데에 적절하지 못한 경우이다.  Levels of evidence

  4. Adult ALL • Leukemic cell burden of up to 1012 cells at Dx • Morphologic CR: 1010 cells • Combination chemotherapy induce CR in 90% of patients • MRD: Post-remission persistence of leukemia that cannot be detected by histomorphologic assessment

  5. Adult ALL, AMC experience P=0.03 III II I Days from DX

  6. Chromosomal abnormalities in ALL

  7. Molecular pathogenesis of CML • 1960 - Shortening of chromosome 22 (Philadelphia chromosome) • 1973 – Translocation of long arm of chromosome 9 to 22 • 1970 - Abelson leukemia virus (v-ABL) • Normal cellular homology (c-ABL)을 chromosome 9의 장완에서 발견 • 그러나 CML 세포의 경우 22번염색체에서 발견 • BCR-ABL chimeric protein 발견 (P210)

  8. Ph-ALL • Ph-ALL is a subset of B-precursor ALL with very poor prognosis. - CR rate of 60-90%; Median CR duration of 6-11 months - rare long term survivor; unless allo-transplanted in CR1. • Imatinib (Glivec): BCR-ABL tyrosine kinase inhibitor- anti-leukemic effect in advanced Ph-ALL - non-overlapping toxicities with cytotoxic chemotherapy • Imatinib alone for newly diagnosed Ph-ALL? - Maximum leukemia reduction of 2.9 log in CML by imatinib alone, which is not likely produce long-term disease control in Ph-ALL. - Additional chromosomal abnormalities in over half cases at Dx. • Anti-leukemic effect and toxicities of combined treatment of imatinib & conventioanl chemotherapy is not known.

  9. A1 : 5' TGA TTA TAG CCT AAG ACC CGG A 3' A2 : 5' ATC TCC ACT GGC CAC AAA ATC ATA CG 3' B1 : 5' GAA GTG TTT CAG AAG CTT CTC C 3' B2 : 5' TGG AGC TGC AGA TGC TGA CCA ACT CG 3' B3 : 5' ACC ATC GTG GGC GTC CGC AAG A 3' B4 : 5' AGA TCT GGC CCA ACG ATG GCG AGG GC 3' Primers used for nested rt-PCR analysis of Bcr-Abl transcripts and their locations on Bcr-Abl fusion cDNA

  10. Bcr-Abl as disease predictor • Positivity correlated with relapse after HCT(10/23+ vs. 2/13- relapses, P=0.025, or=5.7) (Radich J et al. Blood , 1997) • Quantitative real-time PCR at 4 weeks of treatment with imatinib correlated with patient survival • (Scheuring U, et al. Blood, 2003)

  11. Results: Patient characteristics

  12. Results: Complete Remission Proportion achieving CR Imatinib+ chemotherapy Chemotherapy alone P=0.11 Days * Started imatinib D1 to D8 of chemo

  13. Results: Clinical courses (5 relapses; 7 deaths) Median follow up of 584 days (range, 45-800) 20 1 early death due to sepsis (D14) 19 CR 3 Relapse (D 89,95, 341) 14 with Allogeneic BMT 2 alive in CR (D 45, 94) 9 alive and NED 1 died with leukemia (D 137) 1 died with leuk post uBMT (D478) 3 died TRM 2 GVHD, 1 int pneu 2 relapsed (post HCT D 279,318) (one died) 1 alive in 2nd CR after haplo-BMT (D69)

  14. Results: Relapse • Five patients relapsed with 2-year projected relapse rate of 38% (vs. 84% in chemo only group). Chemo only (n=15) P=0.031 Chemo+imatinib (n=19)

  15. Overall survival • Seven died (1 sepsis during induction tx, 3 relapsed leukemia, 3 TRM after allo HCT) with 2-year projected survival rate of 48% (vs. 22% in chemo only group). Chemo+imatinib (n=20) P=0.05 Chemo only (n=18)

  16. Serial quantitative rt-PCR for Bcr-Abl transcripts (I)

  17. Serial quantitative rt-PCR for Bcr-Abl transcripts (II)

  18. Serial plotting of the amount of Bcr-Abl transcripts as expressed by Bcr-Abl/G6PDH ratio. Assuming negative results are 4.5 log reduction from the base line, the median (range) log-reductions from the baseline are 2.13 (0.63-4.5) at CR, 3.60 (1.0-4.5) after 1st consolidation, 4.36 (3.41-4.73) after 2nd consolidation and 3.81 (1.52-4.5) at HCT.

  19. PCR for Ig H gene rearrangement • Ig H gene (variable, diversity, and joining segments) • Unique clonal complementarity-determining region 3 (CDR3), detected by fingerprint, sensitivity 1/103 • CDR3 further analyzed for DNA sequence and allele specific oligonucleotide with sensitivity 1/104 (Mortuza F et al, J Clin Oncol 2002)

  20. MRD detection using Ig H rearrangement in adult ALL • 85/110 diagnostic bone marrow samples (77%) showed rearrangement of VH-(DH)-JH. • 50 cases (59%) had1clone, 18 cases(21%) had 2clones, and17 cases(20%) had 3 or moreclones. • All clones needed to be followed for MRD detection. • 21 of 85 cases showed positive finerprinting while clinically in CR. 18 of 21 subsequently relapsed • Among 64 cases with negative fingerprinting, test with allele specific primer (ASO) were feasible in 32 cases. 9 cases were positive with 6 cases relapsing subsequently. • Among 23 cases where bothfingerprinting andASO tests were negative, 6 relapsed. • Among 32 cases where ASO test was not feasible, 7 cases relapsed. (Mortuza F et al, J Clin Oncol 2002)

  21. MRD detected by Ig H showed significant correlation with disease free survival • Only 77% had suitable fingerprinting marker • Tedious with need for sequencing in significant number of patients

  22. Options for MRD in ALL

More Related